Literature DB >> 11100967

Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features.

P M Beringer1, M D Appleman.   

Abstract

Pulmonary infections continue to be a significant source of morbidity and mortality among patients with cystic fibrosis. Although our understanding of the pathogenesis and clinical consequences of pulmonary infections with Pseudomonas aeruginosa has increased greatly in recent years, very little is known about potentially emerging pathogens such as Burkholderia cepacia complex, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and methicillin-resistant Staphylococcus aureus. In this review, the authors discuss methods for appropriate identification of these "unusual" organisms and their epidemiologic and clinical features. Multicenter surveillance studies are needed to more clearly establish the pathogenicity of these organisms.

Entities:  

Mesh:

Year:  2000        PMID: 11100967     DOI: 10.1097/00063198-200011000-00015

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  14 in total

1.  Pneumonia due to Bordetella bronchiseptica in a cystic fibrosis patient: 16S rRNA sequencing for diagnosis confirmation.

Authors:  Frédéric Wallet; Thierry Perez; Sylvie Armand; Benoit Wallaert; René J Courcol
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

2.  Direct PCR detection of Burkholderia cepacia complex and identification of its genomovars by using sputum as source of DNA.

Authors:  Pavel Drevínek; Hana Hrbácková; Ondrej Cinek; Jana Bartosová; Otakar Nyc; Alexandr Nemec; Petr Pohunek
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

3.  Combination of 16S rRNA variable regions provides a detailed analysis of bacterial community dynamics in the lungs of cystic fibrosis patients.

Authors:  Melissa S Doud; Michael Light; Gisela Gonzalez; Giri Narasimhan; Kalai Mathee
Journal:  Hum Genomics       Date:  2010-02       Impact factor: 4.639

4.  Prevalent bacterial species and novel phylotypes in advanced noma lesions.

Authors:  B J Paster; W A Falkler Jr; C O Enwonwu; E O Idigbe; K O Savage; V A Levanos; M A Tamer; R L Ericson; C N Lau; F E Dewhirst
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

5.  Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center.

Authors:  Sabine Van Daele; Rita Verhelst; Geert Claeys; Gerda Verschraegen; Hilde Franckx; Leen Van Simaey; Catharine de Ganck; Frans De Baets; Mario Vaneechoutte
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

6.  Spontaneous septic arthritis caused by Burkholderia cepacia.

Authors:  Roberto Augusto Miki; Lee Eric Rubin; Jessica Kirk; Seth D Dodds
Journal:  Iowa Orthop J       Date:  2006

Review 7.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

8.  Ralstonia pickettii-induced ataxia in immunodeficient mice.

Authors:  Marion Berard; Christine Medaille; Meredith Simon; Stéphanie Serre; Kathleen Pritchett-Corning; Virginie Dangles-Marie
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

9.  Alcaligenes xylosoxidans endocarditis of a prosthetic valve and pacemaker in a 62-year-old woman.

Authors:  Abhishek C Sawant; Sanjay S Srivatsa; Luis J Castro
Journal:  Tex Heart Inst J       Date:  2013

10.  Metagenomic analysis of respiratory tract DNA viral communities in cystic fibrosis and non-cystic fibrosis individuals.

Authors:  Dana Willner; Mike Furlan; Matthew Haynes; Robert Schmieder; Florent E Angly; Joas Silva; Sassan Tammadoni; Bahador Nosrat; Douglas Conrad; Forest Rohwer
Journal:  PLoS One       Date:  2009-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.